Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.75 |
| ▸ | GSK3A | P49840 | 3/20 | 0.75 |
| ▸ | RGS4 | P49798 | 9/20 | 0.72 |
| ▸ | RGS8 | P57771 | 8/20 | 0.72 |
| ▸ | PRKCA | P17252 | 2/20 | 0.65 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.56 |
| ▸ | CDK1 | P06493 | 1/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.56 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13517354 | 0.89 | RGS4 (0.74) | GSK3BGSK3ARGS4RGS8PRKCA | |
| SCHEMBL2107216 | 0.87 | GSK3B (1.00) | GSK3BGSK3ARGS4RGS8PRKCA | |
| SCHEMBL2107221 | 0.84 | RGS4 (1.00) | GSK3BGSK3ARGS4RGS8PRKCA | |
| SCHEMBL13517234 | 0.83 | RGS4 (1.00) | GSK3BGSK3ARGS4RGS8CCNB2 | |
| SCHEMBL13517060 | 0.83 | RGS4 (0.90) | GSK3BRGS4RGS8PRKCAPOLB | |
| SCHEMBL5023670 | 0.80 | GSK3A (0.67) | GSK3BGSK3ARGS4RGS8CCNB2 | |
| Krm-7777 SCHEMBL3384141 | 0.79 | GSK3B (1.00) | GSK3BGSK3ARGS4RGS8PRKCA | |
| SCHEMBL15212631 | 0.79 | GSK3B (0.78) | GSK3BGSK3ARGS4RGS8PRKCA | |
| SCHEMBL13516989 | 0.78 | RGS4 (0.89) | RGS4RGS8POLBGAAMAPK1 | |
| SCHEMBL29239098 | 0.78 | GSK3B (0.75) | GSK3BGSK3ARGS4RGS8PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4340832-A1 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | Amo Pharma Ltd. (GB) | 2024-03-27 | — | — | EP | claimed |
| EP-4094760-A1 | THIADIAZOLIDINONES FOR THEIR USE IN THE TREATMENT OF LIMB-GIRDLE MUSCULAR DYSTROPHY | Consejo Superior De Investigaciones Científicas (ES) | 2022-11-30 | — | — | EP | claimed |
| WO-2022243973-A1 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | AMO PHARMA LTD. (GB) | 2022-11-24 | — | — | WO | claimed |
| WO-2011151359-A1 | COMBINED TREATMENT WITH A CHOLINESTERASE INHIBITOR AND A THIADIAZOLIDINEDIONE DERIVATIVE | NOSCIRA, S.A. (ES) | 2011-12-08 | — | — | WO | claimed |
| EP-4340832-A1 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | Amo Pharma Ltd. (GB) | 2024-03-27 | — | — | EP | disclosed |
| US-20230241038-A1 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | AMO PHARMA LTD. (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20230241038-A1 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | AMO PHARMA LTD. (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20220387399-A1 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | AMO PHARMA LTD. (GB) | 2022-12-08 | — | — | US | disclosed |
| EP-4094760-A1 | THIADIAZOLIDINONES FOR THEIR USE IN THE TREATMENT OF LIMB-GIRDLE MUSCULAR DYSTROPHY | Consejo Superior De Investigaciones Científicas (ES) | 2022-11-30 | — | — | EP | disclosed |
| WO-2022243973-A1 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | AMO PHARMA LTD. (GB) | 2022-11-24 | — | — | WO | disclosed |
| US-8158661-B2 | GSK-3 inhibitors | NOSCIRA, S.A. (ES) | 2012-04-17 | — | — | US | disclosed |
| US-8158661-B2 | GSK-3 inhibitors | NOSCIRA, S.A. (ES) | 2012-04-17 | — | — | US | disclosed |
| US-7531561-B2 | GSK-3 inhibitors | NOSCIRA, S.A. (ES) | 2009-05-12 | — | — | US | disclosed |
| US-20080153886-A1 | Use Of Heterocyclic Compounds As Neurogenic Agents | NEUROPHARMA, S.A. (ES) | 2008-06-26 | — | — | US | disclosed |
| US-20080153886-A1 | Use Of Heterocyclic Compounds As Neurogenic Agents | NEUROPHARMA, S.A. (ES) | 2008-06-26 | — | — | US | disclosed |
| WO-2005097117-A1 | THIADIAZOLIDINONES AS GSK-3 INHIBITORS | NEUROPHARMA, S.A. (ES) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005097117-A1 | THIADIAZOLIDINONES AS GSK-3 INHIBITORS | NEUROPHARMA, S.A. (ES) | 2005-10-20 | — | — | WO | disclosed |
| EP-1586318-A1 | Thiadiazolidinones as GSK-3 inhibitors | Neuropharma S.A.U. (ES) | 2005-10-19 | — | — | EP | disclosed |
| EP-1586319-A1 | Thiadiazolidinones as GSK-3 inhibitors | Neuropharma S.A. (ES) | 2005-10-19 | — | — | EP | disclosed |
| US-20050222220-A1 | GSK-3 inhibitors | NEUROPHARMA, S.A. (ES) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387399-A1 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | TRDMT1, HNRNPDL, HNRNPD | GSK3B 3391/4885GSK3A 4037/4885RGS4 3507/4885 |
| US-20050222220-A1 | GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | GSK3B 1/4885GSK3A 2/4885RGS4 4483/4885 |
| US-20080153886-A1 | Use Of Heterocyclic Compounds As Neurogenic Agents | GAP43, NGF, BDNF | GSK3B 848/4885GSK3A 945/4885RGS4 3784/4885 |
| US-20230241038-A1 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | TRDMT1, HNRNPDL, HNRNPD | GSK3B 3391/4885GSK3A 4037/4885RGS4 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.